MYC-mediated synthetic lethality for treating tumors
- PMID: 25553514
- DOI: 10.2174/1568009615666150121162921
MYC-mediated synthetic lethality for treating tumors
Abstract
Deregulated c-MYC (hereafter MYC) is widely expressed in many human tumors. Myctransgenic mouse models produce diverse tumors. MYC is a strong driver of tumorigenesis and is required for tumor maintenance. MYC is therefore an attractive target for cancer treatment. However, genetic and pharmacological approaches for the targeted inactivation of MYC for the treatment of MYC-overexpressing tumors have been shown to be unsatisfactory. MYC expression is regulated by different mechanisms at transcriptional, post-transcriptional, and post-translational levels. Turnover of MYC protein is an important step that influences the expression and function of MYC. MYC turnover is predominantly controlled by the GSK3/FBW7 axis that is regulated by multiple elements. Small molecule inhibitors (SMIs) can influence the stability and activity of MYC protein by targeting the axis and its regulator elements. Wang et al. (2004) first introduced the concept of MYC-mediated synthetic lethality (MYC-SL) induced by TRAIL and DR5-agonists. Researchers have turned to synthetic lethality as a treatment strategy for MYC-overexpressing tumors. MYC function is closely associated with MYC levels. Two strategies have been developed to treat MYC-overexpressing tumors by upregulating or downregulating MYC. An SMI can induce MYC-SL by increasing MYC expression through the inactivation of the GSK3β/FBW7 axis and CK1. Elevated MYC levels lead to DNA damage, senescence, and apoptosis. An SMI can also induce MYC-SL by decreasing MYC expression through the activation of the GSK3β/FBW7 axis, the inactivation of PP2A inhibitors, and the inhibition of ARK5, AUK-A, Brd4, CDK1, CDK2, CHK1, and SAE1/2. Reduced MYC levels cause tumor regression. Some SMIs have entered phase I and II clinical trials. SMIs may be used in the near future to treat cancers co-overexpressing MYC and the corresponding MYC-SL genes.
Similar articles
-
MYC-mediated synthetic lethality for treatment of hematological malignancies.Curr Cancer Drug Targets. 2015;15(1):53-70. doi: 10.2174/1568009615666150105120055. Curr Cancer Drug Targets. 2015. PMID: 25564254 Review.
-
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function.Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15195-200. doi: 10.1073/pnas.0505114102. Epub 2005 Oct 6. Proc Natl Acad Sci U S A. 2005. PMID: 16210249 Free PMC article.
-
Attacking c-Myc: targeted and combined therapies for cancer.Curr Pharm Des. 2014;20(42):6543-54. doi: 10.2174/1381612820666140826153203. Curr Pharm Des. 2014. PMID: 25341931 Review.
-
MYC as a target for cancer treatment.Cancer Treat Rev. 2021 Mar;94:102154. doi: 10.1016/j.ctrv.2021.102154. Epub 2021 Jan 19. Cancer Treat Rev. 2021. PMID: 33524794 Review.
-
Taking on challenging targets: making MYC druggable.Am Soc Clin Oncol Educ Book. 2014:e497-502. doi: 10.14694/EdBook_AM.2014.34.e497. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857145 Free PMC article. Review.
Cited by
-
Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.Molecules. 2018 Oct 28;23(11):2798. doi: 10.3390/molecules23112798. Molecules. 2018. PMID: 30373318 Free PMC article. Review.
-
Strategies to Inhibit Myc and Their Clinical Applicability.Front Cell Dev Biol. 2017 Feb 23;5:10. doi: 10.3389/fcell.2017.00010. eCollection 2017. Front Cell Dev Biol. 2017. PMID: 28280720 Free PMC article. Review.
-
Altering MYC phosphorylation in the epidermis increases the stem cell population and contributes to the development, progression, and metastasis of squamous cell carcinoma.Oncogenesis. 2020 Sep 7;9(9):79. doi: 10.1038/s41389-020-00261-3. Oncogenesis. 2020. PMID: 32895364 Free PMC article.
-
MYC alterations in multiple myeloma: Genetic insights and prognostic impact.Neoplasia. 2025 Aug;66:101177. doi: 10.1016/j.neo.2025.101177. Epub 2025 May 14. Neoplasia. 2025. PMID: 40375408 Free PMC article. Review.
-
Comparative analysis of compound NSC13728 as Omomyc homodimer stabilizer by molecular dynamics simulation and MM/GBSA free energy calculation.J Mol Model. 2022 Mar 16;28(4):92. doi: 10.1007/s00894-022-05082-2. J Mol Model. 2022. PMID: 35294626
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous